Recommendations for appropriate sublingual immunotherapy clinical trials

World Allergy Organization Journal

Volumn 7, Issue 1, 2014, Pages

  Passalacqua, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; PLACEBO;

ADVERSE DRUG REACTION; ALLERGY; ANTIGEN SPECIFICITY; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXPERIMENTAL STUDY; HEALTH CARE ORGANIZATION; HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; SUBLINGUAL IMMUNOTHERAPY; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84988936179     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/1939-4551-7-21     Document Type: Review

References (37)

1. Bernstein D, Wanner M, Borish L, Liss GM: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2001, 113:1129-1136.
2. World Health Organization Position Paper: Allergen immunotherapy: therapeutical vaccines for allergic diseases. Bousquet J, Lockey R, Malling HJ edts. Allergy 1998, 53(supp):1-33.
3. Bousquet J, Kalthaev N, Van Cauwenberge P (Eds): Allergic Rhinits and its Impact on Asthma. J Allergy Clin Immunol 2001, 108(5 supp):S146-S150.
4. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderón M, Compalati E, Durham SR, van Wijk RG, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, RosǍrio N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna G, Valovirta E, Van Bever H, Vichyanond P, Wahn U, Yusuf O: Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014, 7:6.
5. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S: Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117(4):802-809.
6. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, Andre C, de Beaumont O, Melac M: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338-45
7. Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60(1):4-12.
8. Radulovic S, Wilson D, Calderon M, Durham S: Sistematic reviews of sublingual immunotherapy (SLIT). Allergy 2011, 66:740-752.
9. Calamita Z, Saconato H, Bronhara Pelà A, Atallah AN: Efficacy of Sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 2006, 61:1162-1172.
10. Penagos M, Compalati E, Tarantini F, Huerta J, Passalacqua G, Canonica GW: Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in children. Meta analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2006, 97:141-148.
11. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, Canonica GW: Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008, 133:599-609.
12. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR: Sublingual immunotherapy for allergic conjunctivitis: cochrane systematic review and meta-analysis. Clin Exp Allergy 2011, 41:1263-1272.
13. Compalati E, Passalacqua G, Bonini M, Canonica GW: The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009, 64:1570-9
14. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G: Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010, 126:558-566.
15. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E: Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007, 62:317-324.
16. Casale T, Canonica GW, Bousquet J, Cox L, Nelson H, Passalacqua G: Recommendations for appropriate sublingual immunotherapy (SLIT) clinical trials. J Allergy Clin Immunol 2009, 124:665-670.
17. Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen KH, Malling HJ, Passalacqua G, Simons FE, Anto J, Baena-Cagnani CE, Bergmann KC, Bieber T, Briggs AH, Brozek J, Calderon MA, Dahl R, Devillier P, Gerth van Wijk R, Howarth P, Larenas D, Papadopoulos NG, Schmid-Grendelmeier P, Zuberbier T: How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy 2011, 66:765-774.
18. Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M: The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013, 3:42. doi:10.1186/2045-7022-3-42.
19. Worm M, Rak S, de Blay F, Malling HJ, Melac M, Cadic V, Zeldin RK: Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy 2014, 11:7.
20. Blaiss M, Nelson HS, Durham SR, Dahl R, Bufe R: Reply to Kette and Smith. J Allergy Clin Immunol 2011, 128:430-432.
21. Calderón MA, Cox L, Casale TB, Moingeon P, Demoly P: Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012, 129:929-934.
22. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C: Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007, 18:47-57.
23. Dahl R, Stender A, Rak S: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006, 61:185-190.
24. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R: SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012, 179:717-725.
25. Scadding G, Hellings P, Alobid I, Bachert C, Fokkens W, van Wijk Gerth R, Gevaert P, Guilemany J, Kalogjera L, Lund V, Mullol J, Passalacqua G, Toskala E, van Drunen C: Diagnostic tools in rhinology EAACI position paper. Clin Transl Allergy 2011, 1:2.
26. Bousquet PJ, Combescure C, Klossek JM, Daurès JP, Bousquet J: Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 2009, 123:1349-1354.
27. Grouin JM, Vicaut E, Jean-Alphonse S, Demoly P, Wahn U, Didier A, de Beaumont O, Montagut A, Le Gall M, Devillier P: The average adjusted symptom score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy 2011, 41:1282-1288.
28. Sander I, Fleischer C, Meurer U, Brüning T, Raulf-Heimsoth M: Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy 2009, 64:1486-1492.
29. Lombardi C, Incorvaia C, Braga M, Senna G, Canonica GW, Passalacqua G: Administration regimens for sublingual immunotherapy: what do we know. Allergy 2009, 64:849-854.
30. Stelmach I, Kaluziňska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P: Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy 2012, 67:312-320.
31. Pajno G, Caminiti L, Vita D, Crisafulli G, Valenzise M, De Luca R, Passalacqua G: Direct comparison between continuous and co-seasonal regimen for sublingual immunotherapy in children with grass allergy. Pediatr Allergy Immunol 2011, 22(8):803-807.
32. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G: Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010, 125:569-574.
33. Passalacqua G, Baena Cagnani C, Bousquet J, Canonica GW, Cox L, Durham S, Larenas Linnemann D, Ledford D, Potter P, Rosario N, Wallace D, Lockey RF: Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013, 132:93-98.
34. Bousquet PJ, Calderon MA, Demoly P, Larenas D, Passalacqua G, Bachert C, Brozek J, Canonica GW, Casale T, Fonseca J, Dahl R, Durham SR, Merk H, Worm M, Wahn U, Zuberbier T, Schünemann HJ, Bousquet J: The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011, 127:49-56.
35. Passalacqua G, Baiardini I, Senna G, Canonica GW: Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy 2013, 43:22-28.
36. Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljørring C, Canonica GW: Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebocontrolled trial. J Allergy Clin Immunol 2014. doi:10.1016/j.jaci.2014.03.019.
37. Creticos PS, Esch RE, Couroux P, Gentile D, D'Angelo P, Whitlow B, Alexander M, Coyne TC: Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 2014, 133:751-758.